Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting …

  • 0 views
  • 28 Jun, 2022
  • 1 location
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma (IPRICE)

This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the …

carcinoma
measurable disease
squamous cell carcinoma
  • 0 views
  • 06 May, 2022
  • 1 location
Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Combination treatment with antiangiogenic agents and anti-programmed cell death protein 1 (PD-1) antibodies have shown high anti-tumor efficacy for patients with unresectable or advanced

tyrosine
cancer
pembrolizumab
  • 0 views
  • 03 Aug, 2021
  • 1 location
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic

programmed cell death 1 ligand 1
programmed cell death protein 1
solid tumour
immunomodulator
  • 0 views
  • 28 May, 2021
  • 1 location
The Clinical Implications of Immune Checkpoint Pathways in PCNSL

been identified. Among them, three have been studied most intensively: cytotoxic T lymphocyte antigen 4 (CTLA4) binding to CD80 or CD86, programmed cell death protein 1 (PD-1) binding to PD-1 ligand 1

hodgkin's disease
gm-csf
colony stimulating factor
cancer
  • 0 views
  • 17 Feb, 2022
  • 1 location
Immuno-Oncology Database and Bioregistry (IOG)

Immunotherapy, especially immune checkpoint inhibitors (ICIs), are effective in treating many different types of cancers. ICIs fight cancer by driving the immune system into an "activated state" that makes it harder for tumor cells to hide and easier for the immune system to destroy them. In doing this, oncologists risk …

primary cancer
cancer
  • 0 views
  • 11 Mar, 2022
  • 1 location
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

Background Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective To better understand liver cancer. Eligibility …

cancer
  • 0 views
  • 24 Jul, 2022
  • 7 locations
Relationship Between Breast Cancer Subtypes and Immune Checkpoints

Breast cancer is the most common type of cancer in women and the second most common cause of death after lung cancer. The luminal group A, which has the highest prevalence among breast cancers; It includes Her2-negative tumors with low proliferative activity, low mitotic rate and histological grade. The prognosis …

  • 0 views
  • 21 Jul, 2022
  • 1 location
Immune Checkpoint Inhibitors Nephrotoxicity

In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through the inhibition of molecules involved in the brake of the adaptive immune response. The compounds capable of blocking the action of …

  • 0 views
  • 04 Jun, 2021
  • 2 locations